D'Vidamax

Quick links to important sections

D'Vidamax

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of D'Vidamax

D'Vidamax is a medicinal preparation and nutritional supplement intended to supply the body with Colecalciferol, the compound commonly identified as Vitamin D3. The comprehensive semantic coverage of this entity focuses strictly on its identity, composition, origin, and general physiological role.

Property Description
Active ingredient Colecalciferol (Vitamin D3)
Form Oral solution, Liquid drops, Capsules, Tablets
Pharmacological class Vitamin D analogue, Fat-Soluble Vitamin
Common use Addressing Vitamin D deficiency/insufficiency
Origin Exogenous source of a natural prohormone

What Type of Medicine is D'Vidamax?

D'Vidamax is fundamentally classified within the Vitamin D analogue and Fat-Soluble Vitamin pharmacological group. This substance is structurally known as a secosteroid and functions as an inactive prohormone, meaning it requires mandatory metabolic steps in the liver and kidneys to become the biologically active hormone, Calcitriol. Colecalciferol is clinically recognized for its superior efficacy in raising serum vitamin D levels compared to the plant-derived Ergocalciferol (Vitamin D2) across various study populations. This compound is the substance produced endogenously in the skin, but when administered via the oral route of administration, it functions as a critical exogenous source to address deficiency states.

Composition, Origin, and Available Forms

The product is a single-ingredient product whose composition is based exclusively on Colecalciferol combined with a suitable delivery medium. As a fat-soluble vitamin, it is frequently formulated into an oily vehicle, such as in liquid drops or soft gelatin capsules, to optimize its assimilation, though it is also available in solid pharmaceutical preparations like film-coated tablets and chewable gel. The availability of D'Vidamax in multiple oral forms—a key differentiating factor—allows for flexible administration tailored to patient groups, such as infants or adults requiring maintenance therapy.

The General Purpose and Physiological Role

The overall purpose of supplying Colecalciferol via D'Vidamax is to facilitate the body’s intrinsic ability to manage key minerals, primarily calcium and phosphate. The availability of this prohormone ensures that the active metabolite can be produced, which then stimulates the efficient intestinal absorption of these minerals. Colecalciferol supplementation is widely endorsed by medical organizations as essential for supporting the skeletal system and plays a necessary part in maintaining proper muscle function, a benefit that is critical for older adults at risk of falls. This confirmed role is central to managing states of vitamin D deficiency and insufficiency.

Regulatory References

  1. MedlinePlus

What side effects are possible with D'Vidamax?

Possible Side Effects and Safety Information

The safety profile for D'Vidamax (Colecalciferol) primarily relates to its effect on mineral balance in the body, which is a potential risk associated with excessive or prolonged intake, as documented in official regulatory labeling.

Adverse Reaction Classification

The most commonly classified safety concerns center around elevated levels of calcium. The regulatory documentation classifies Hypercalcaemia (excess calcium in the blood) and Hypercalciuria (excess calcium in the urine) as Uncommon adverse reactions.

Less frequently, general effects may be noted. Adverse reactions such as pruritus (itching), rash, and urticaria (hives) are classified as Rare. Gastrointestinal effects, which may include constipation, flatulence, nausea, abdominal pain, or diarrhea, have also been documented, though their frequency is often classified as Not Known.

Organ Systems and Serious Reactions

Adverse effects are categorized by the systems affected, chiefly Metabolism and Nutrition Disorders and Renal and Urinary Disorders. Serious adverse reactions are typically consequences of severe, unmanaged hypercalcaemia, including the risk of Nephrocalcinosis (calcification of the kidneys) and Urolithiasis (kidney stones).

Safety Restrictions and Population Notes

The medicine is contraindicated and should not be used in individuals with pre-existing conditions such as Hypercalcaemia, Hypercalciuria, Hypervitaminosis D, or severe renal impairment. Safety notes advise caution for specific populations, including patients with sarcoidosis and infants and toddlers, who may be more susceptible to hypercalcaemia and require particular attention according to regulatory authorities. The primary safety concern is strongly associated with cumulative overexposure (chronic toxicity) rather than appropriate short-term use.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of D'Vidamax, which contains Colecalciferol (Vitamin D3), results in a condition officially documented as Hypervitaminosis D, which leads to dangerously elevated calcium levels in the blood, known as Hypercalcemia. This is the core pathological state defined in regulatory documents.


Documented Manifestations and Severe Outcomes

Overdose may present with systemic manifestations, including general symptoms such as fatigue, nausea, vomiting, and excessive thirst (polydipsia). Specific signs include frequent urination (polyuria) and severe constipation. Severe or chronic overdose can escalate to life-threatening complications, including cardiac arrhythmias, confusion, and potentially irreversible organ damage such as renal failure and widespread soft tissue calcification.


Emergency Action and Supportive Management

Due to the risk of severe toxicity, the official regulatory guidance mandates seeking immediate medical attention and discontinuing the Colecalciferol product upon suspicion of overdose. There is no specific antidote for Colecalciferol overdose documented in the official labeling. Management is strictly supportive and symptomatic, focusing on rehydration and correcting hypercalcemia. Monitoring requirements include continuous observation of serum calcium levels, renal function, and, in cases of severe toxicity, an ECG (Electrocardiogram). Overdose must be strictly avoided during pregnancy due to the officially documented risk of developmental complications in the fetus.

Therapeutic Uses of D'Vidamax

D'Vidamax (Colecalciferol) is commonly used to help with the correction and management of states of Vitamin D deficiency or insufficiency, which plays a supportive role in structural integrity. This substance helps the body to use absorbed calcium and phosphate effectively, which is important for bone health. This use is relevant for easing the symptoms related to bone health and mineral balance.

The medication is relevant for conditions characterized by periods of heightened symptoms, including Osteomalacia, Rickets, and as part of the supportive management of Osteoporosis. It is applied in clinical settings that involve systemic imbalance, often when patients experience non-specific bone pain and generalized muscle weakness that creates noticeable physiological strain. It assists with maintaining functional stability and coordination, and supports the patient during difficult episodes by easing distress related to structural compromise.

“It is relevant when supportive symptom management is appropriate, particularly where chronic deficiency interferes with routine physical comfort.”


Quick Fact: Symptom Management for Musculoskeletal Discomfort and Functional Weakness

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

D'Vidamax (Colecalciferol) is permitted for use in the general population, including most adults, babies, and children. However, regulatory documents establish strict contraindications prohibiting its use in certain patient groups.

Contraindicated Populations

The medicine is contraindicated in individuals with established evidence of Hypercalcemia (high blood calcium), Hypercalciuria (high urine calcium), or Hypervitaminosis D. Use is also prohibited for patients with Hypersensitivity to Colecalciferol or its excipients, Severe Renal Impairment, and those with Nephrolithiasis (kidney stones).

Restricted and Conditional Use

Caution is required in patients with Sarcoidosis or Hyperparathyroidism due to risks related to Vitamin D metabolism. While Hepatic Impairment typically does not require a specific restriction, use is strictly contraindicated in severe kidney disease and requires close monitoring in general renal impairment.

Use during Pregnancy and Lactation is permitted only up to a specific daily limit, which generally must not exceed 4,000 IU (100 mcg). Although use in children is generally established, specific data regarding the relationship of age to the effects in Geriatric Patients is often not available in official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for D'Vidamax (Colecalciferol) focuses on substances that modify systemic exposure and those that pose a pharmacodynamic risk related to mineral balance.

Documented Interaction Patterns

Anticonvulsant medicines such as phenytoin and fosphenytoin are officially documented to increase the catabolism (breakdown) of Colecalciferol, a pharmacokinetic effect that may necessitate changes in intake. Conversely, other agents interfere with the intestinal absorption of this fat-soluble vitamin. Mineral oil, Orlistat, and Bile Acid Sequestrants (e.g., Cholestyramine) are noted in regulatory documents for impairing Colecalciferol uptake.

Pharmacodynamic interactions arise with substances that share or enhance the effect on calcium levels. Co-administration with thiazide diuretics may cause hypercalcemia due to an additive effect on reducing renal calcium excretion. Additionally, the risk of Digoxin toxicity is officially linked to the potential for hypercalcemia resulting from Colecalciferol use.

Restrictions and Timing Rules

Regulatory labels advise against co-administration with other Vitamin D analogs due to the potential for additive toxicity. Specific timing rules exist for certain agents: Colecalciferol must be separated from Orlistat by at least two hours and from aluminum-containing antacids by a specific four-hour window to minimize interaction. Grapefruit or grapefruit juice consumption is also officially noted as potentially altering Colecalciferol blood levels.

Mechanism of Action

VDR Agonism and Gene Transcription

D'Vidamax's active metabolite functions as an agonist for the Vitamin D Receptor (VDR), a nuclear transcription factor expressed across multiple tissues. This binding action triggers an intracellular cascade, forming a complex that modulates gene expression by targeting specific DNA sequences. The molecular consequence is the alteration of protein synthesis, including key transport proteins like Calbindin, which precedes the downstream effects on mineral regulation.


Central Regulation of Calcium and Phosphate Homeostasis

This mechanism dictates the systemic handling of calcium and phosphate across three peripheral systems: the gastrointestinal tract, the kidneys, and bone. In the intestine, it increases mineral absorption. In the kidney, it promotes reabsorption, minimizing urinary loss. This coordinated action results in the adjustment of circulating mineral concentrations.


Modulating Skeletal and Endocrine Dynamics

The final cascade involves the mechanism's influence on bone metabolism and Parathyroid Hormone ( PTH) secretion. By facilitating mineral availability and directly affecting bone-regulating cells, the mechanism supplies the necessary precursors required for bone matrix calcification (mineralization) and modulates the secretion of PTH.

Dosage and Administration Information

How D'Vidamax is Used: Administration Protocol

The usage protocol for D'Vidamax (Colecalciferol) is strictly defined by regulatory documents, focusing on the method of delivery and the required dosing schedule. The medicine is administered via the oral route, consistent with its formulation as tablets, capsules, and liquid solutions. The general regimen is phased, moving from a short-term, high-magnitude corrective phase to a long-term, lower-dose maintenance phase.

Route and General Dosing Pattern

The corrective phase involves high-dose, intermittent administration, such as 50,000 International Units (IU) taken once per week for a defined duration, typically 6 to 12 weeks, to rapidly normalize bodily levels. The subsequent maintenance phase involves a continuous daily dose, which commonly ranges from 800 IU to 2,000 IU.

Procedural Administration Conditions

Official instructions stipulate that due to its nature as a fat-soluble compound, Colecalciferol is optimally absorbed when taken with a meal that contains fat. For liquid formulations, accurate delivery is procedural: the dose must be measured using the calibrated dispensing device supplied with the product, not household spoons.

Age-Specific and Timing Rules

The official administration pattern for long-term use requires consistency, ideally taking the medicine at the same time each day. Age-specific instructions define that older adults may require daily maintenance doses toward the higher range (up to 2,000 IU) due to reduced synthesis capacity. If a missed dose occurs during a continuous daily regimen, official guidance states that it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is omitted to avoid procedural error.

Recent Clinical Evidence

Research on Vitamin D Status

Research, primarily Randomized Controlled Trials (RCTs) and systematic reviews, examined D'Vidamax in individuals with low vitamin D levels. Studies monitored changes in the 25-hydroxyvitamin D [25(OH)D] biomarker as an outcome related to systemic imbalance. Findings describe patterns observed where biomarker status changed during the study period. However, the certainty regarding optimal target levels remains low, as a precise universal target is not definitively established. Furthermore, follow-up durations were limited in some research exploring short-term changes in status.

Research on Deficiency-Related Bone Diseases

Research was conducted in individuals with conditions like Rickets (children) and Osteomalacia (adults). These deficiency diseases are associated with profound systemic imbalance and skeletal structural changes. Studies explored outcomes related to physical discomfort and changes in bone tissue mineralization. Research describes patterns related to the clinical features and skeletal structural compromises. Comparative evidence is lacking from modern, large-scale RCTs, as management is largely documented in existing protocols.

Research on Bone Health and Functional Measures

Large RCTs and systematic reviews were evaluated in older adults, examining outcomes related to bone health such as fall frequency, fracture incidence, and Bone Mineral Density (BMD). Data related to fracture incidence were mixed; patterns were associated with co-administration of calcium in some trials. Variability exists across studies, leading to inconsistent findings. Research provides context regarding group patterns, but the durability of these short-term changes requires continued investigation.

Long-Term Studies and Research Gaps

Studies explored D'Vidamax over defined time intervals (initial protocols to extended maintenance). While research provides insight into short-term changes, patterns observed over many years are not fully established regarding the durability of measured status and skeletal outcomes. Key limitations include the heterogeneity (variability) across existing research and the insufficiency of data for certain groups. Research highlights what is known — and what is still uncertain.

Key Studies & References

  1. Vitamin D Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about D'Vidamax (FAQ)


Q: How does D'Vidamax differ from other commonly prescribed medications for the same condition?

Official documents classify D'Vidamax (Colecalciferol) as a Vitamin D analogue, specifically D3. It is structurally different from related vitamin D products, such as Calcitriol. Regulatory texts also note that studies have described its use and efficacy in comparison to Ergocalciferol (Vitamin D2).


Q: What are the most common side effects listed for D'Vidamax?

Reported adverse reactions are generally related to elevated calcium levels in the body, which is known as hypercalcaemia. Gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and constipation have been documented. Official frequency data for many of these effects is often listed as uncommon or unknown.


Q: Are there any specific foods or drinks that should be avoided while taking D'Vidamax?

According to official product information, certain foods and drinks may alter how the medicine works. Grapefruit or grapefruit juice is specifically noted as a substance that could potentially change Colecalciferol blood levels. Conversely, because the medicine is fat-soluble, optimal absorption is achieved when it is taken alongside a meal that contains fat.


Q: What kinds of non-prescription medications or supplements might interact with D'Vidamax?

Caution is advised in official documents regarding certain non-prescription items that can affect calcium levels. This includes other Vitamin D analogues, as well as calcium and phosphorus supplements. Co-administration of these items may increase the risk of hypercalcaemia, and the use of these items concurrently is subject to careful medical supervision.


Q: Is D'Vidamax safe to use for people who have liver issues?

Official regulatory information generally states that a specific dose adjustment is not required for individuals with hepatic (liver) impairment. However, some liquid formulations of the medicine may contain alcohol. Regulatory warnings note that caution is advised for populations where alcohol intake must be limited.


Q: Is D'Vidamax generally safe for older adults (the elderly)?

Official regulatory labeling confirms that Colecalciferol is indicated for use in the elderly population. The specific dose required is typically determined by a healthcare professional based on the individual's existing vitamin D status.


Q: Are there specific symptoms that should prompt a person to contact a healthcare professional immediately while taking D'Vidamax?

Signs of a severe allergic reaction, such as difficulty breathing or swelling of the face, tongue, or throat, are considered medical emergencies that must be reported immediately. Reporting is also warranted for severe symptoms of acute hypercalcaemia, which may include intense vomiting, profound confusion, or severe bone pain.


Q: Does D'Vidamax interact with common over-the-counter pain relievers?

Regulatory documents for some combination products containing Colecalciferol specifically list Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) as an interaction that requires consideration. Concurrent use of these drugs requires medical consideration.


Q: Does D'Vidamax have a risk of allergic reaction, and what are the signs?

Hypersensitivity to any component of the product is listed as a contraindication in official documents. Adverse skin reactions, such as rash, pruritus (itching), and urticaria (hives), have been reported rarely. Swelling of the face or tongue may be a sign of a serious allergic reaction.


Q: Are there any long-term health risks associated with taking D'Vidamax for an extended period?

Official guidelines mandate the monitoring of serum calcium levels and renal (kidney) function during prolonged use. Chronic overexposure may result in hypercalcaemia, which carries the risk of irreversible calcification in soft tissues or organs.


Q: Are there specific warnings or precautions about D'Vidamax for teenagers or children?

The medicine is indicated for use in children and adolescents, but the correct dose is established by a healthcare professional. Official warnings indicate that it is contraindicated in severe kidney impairment and should be used with caution in infants and toddlers.


Q: Does the efficacy of D'Vidamax change over time?

Pharmacokinetic studies indicate that the primary storage form of Colecalciferol is eliminated slowly from the body. The apparent half-life in the serum is approximately 50 days, which indicates a durable systemic presence.


Q: Does D'Vidamax affect hormone levels in men or women?

The biologically active form of D'Vidamax is confirmed in official documents to directly inhibit the production and secretion of Parathyroid Hormone (PTH). This action is central to its mechanism for regulating mineral balance in the body.


Q: Are there any specific dietary requirements while on D'Vidamax therapy?

Regulatory information indicates that Colecalciferol is a fat-soluble substance. Therefore, optimal absorption is achieved when it is taken after a meal that contains fat.


Q: What is the expected timeline for D'Vidamax to start having an effect?

Pharmacokinetic data describes the time frame for the drug's absorption and processing in the body. Following a single oral dose, the maximum serum concentration of the primary storage form of the drug is reached after approximately seven days.


Q: Does D'Vidamax have any known effects on mental clarity or focus?

Adverse effects that have been reported include dizziness and mental disturbances. These symptoms are primarily linked to hypercalcaemia, which is a key safety concern.


Q: Does D'Vidamax cause weight gain or weight loss?

Symptoms of acute or chronic overdose have been reported to include a loss of appetite, which is known as anorexia, as well as weight loss.


Q: Are there any specific laboratory tests required before starting D'Vidamax?

Regulatory documents indicate that the pre-existence of conditions such as high calcium levels (hypercalcaemia) and kidney stones is assessed before starting treatment. Furthermore, long-term use requires periodic monitoring of serum calcium and renal (kidney) function, which involves blood and urine tests.


Q: Can D'Vidamax affect a person's ability to drive or operate machinery?

Official regulatory text specifically states that Colecalciferol has no or negligible influence on the ability to drive and use machines.


Q: Is it normal to feel a change in energy levels after starting D'Vidamax?

Reports of adverse effects have included unusual tiredness, weakness, and fatigue. These effects have been reported as side effects or as symptoms associated with overdose.


Q: Does D'Vidamax interact with alcohol consumption?

While a definitive interaction is not widely cited, some liquid products may contain a small amount of alcohol. Official warnings indicate that caution is required for patients with conditions where alcohol intake must be limited, such as certain liver diseases.


Q: Are there any known issues with D'Vidamax and sun exposure?

The body naturally produces Colecalciferol when the skin is exposed to UV radiation. Regulatory documents indicate that minimizing sun exposure is a management strategy used for individuals with hypercalcaemia due to overexposure or overdose.


Q: Can D'Vidamax be crushed, split, or chewed?

Administration instructions vary based on the specific dosage form. Official labeling indicates certain forms, like chewable wafers, are required to be chewed or crushed. Similarly, liquid forms are designed to be measured using the calibrated dispensing device provided with the product.

How should D'Vidamax be stored and disposed of?

The official regulatory requirements for storing and disposing of D'Vidamax (Colecalciferol/Vitamin D3) ensure product stability and safety.

Storage Conditions

The product must be stored at room temperature, generally not above 25°C (77°F). It is mandatory to protect from light and moisture by keeping the medicine in its original package and outer carton. Do not freeze the medicine. All forms must be kept out of the sight and reach of children.

Stability and Disposal

For oral solutions, official labeling requires the product to be discarded 60 days after first opening. Unused or expired D'Vidamax must not be thrown away via wastewater or household waste. Disposal must follow local procedures, and the pharmacist should be consulted for instructions on discarding unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of D'Vidamax found in:

A-Z Index: